Daily Respiratory Research Analysis
Top findings today span therapy, diagnostics, and prevention in respiratory health: a phase 3 RCT confirms sustained overall survival benefit of serplulimab plus chemotherapy in extensive-stage small-cell lung cancer and proposes protein and genomic biomarkers. A bioinspired, pump-free microfluidic platform enables rapid, low-cost multiplex nucleic acid testing for influenza A/B and SARS-CoV-2 with near–qPCR sensitivity. Real-world data from Argentina show maternal RSVpreF vaccination substantia
Summary
Top findings today span therapy, diagnostics, and prevention in respiratory health: a phase 3 RCT confirms sustained overall survival benefit of serplulimab plus chemotherapy in extensive-stage small-cell lung cancer and proposes protein and genomic biomarkers. A bioinspired, pump-free microfluidic platform enables rapid, low-cost multiplex nucleic acid testing for influenza A/B and SARS-CoV-2 with near–qPCR sensitivity. Real-world data from Argentina show maternal RSVpreF vaccination substantially reduces infant RSV hospitalizations and disease severity.
Research Themes
- Immunotherapy and biomarkers in lung cancer
- Point-of-care multiplex diagnostics for respiratory viruses
- Maternal immunization to prevent infant RSV disease
Selected Articles
1. First-line serplulimab plus chemotherapy in extensive-stage small-cell lung cancer: Updated results and biomarker analysis from the ASTRUM-005 randomized clinical trial.
In this phase 3 RCT (n=585), first-line serplulimab plus carboplatin/etoposide improved median OS to 15.8 vs 11.1 months (HR 0.62, P<0.001) compared with chemotherapy alone. Exploratory analyses identified a 15-protein serum signature and RB1/Notch pathway mutations associated with better outcomes in the serplulimab arm; baseline NLR and LDH were independent prognosticators.
Impact: Confirms durable survival benefit of PD-1 blockade plus chemotherapy in ES-SCLC and proposes pragmatic biomarker strategies to enrich for responders.
Clinical Implications: Serplulimab plus carboplatin/etoposide should be considered a first-line standard option in ES-SCLC. The 15-protein signature and RB1/Notch mutations may guide future patient selection; NLR and LDH can aid risk stratification.
Key Findings
- Median OS improved to 15.8 vs 11.1 months (HR 0.62; 95% CI 0.50–0.76; P<0.001) with serplulimab plus chemotherapy.
- A 15-protein serum signature predicted longer OS and PFS in the serplulimab arm.
- RB1 mutations and Notch pathway mutations were associated with improved ORR/OS/PFS among treated patients.
- Baseline NLR and LDH independently predicted prognosis in ES-SCLC.
Methodological Strengths
- Randomized, placebo-controlled phase 3 design with n=585 and extended median follow-up (19.8 months).
- Preplanned exploratory proteomic and genomic biomarker analyses with regression modeling.
Limitations
- Biomarker analyses are exploratory and require external validation.
- Study population/geographies may limit generalizability beyond trial settings.
Future Directions: Validate the 15-protein signature and RB1/Notch-based predictors prospectively; integrate biomarker-driven selection in future trials and real-world cohorts.
BACKGROUND: The ASTRUM-005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive-stage small-cell lung cancer (ES-SCLC). Here, we report updated efficacy and safety results after an extended median follow-up of 19.8 months, along with the first report on findings from exploratory biomarker analyses. METHODS: A total of 585 patients were randomized in a 2:1 ratio to receive 4.5 mg/kg serplulimab (n = 389) or placebo (n = 196) intraven
2. A Bioinspired Microfluidic Nucleic Acid Sensing Platform for Rapid and Simultaneous Screening of Viral Respiratory Infections.
A gravity-assisted, root-hair-inspired microfluidic platform achieves pump-free, hand-held multiplex nucleic acid testing for influenza A/B and SARS-CoV-2. It delivers visual results within 40 minutes with ~0.18 copies/µL LoD, 93.2% sensitivity and 97.7% specificity on retrospective clinical samples, at ≈$1.4/test.
Impact: Provides a highly innovative, low-cost, and deployable POCT solution for multiplex respiratory virus screening with performance approaching qPCR, addressing access barriers in low-resource settings.
Clinical Implications: Can support rapid triage and decentralized outbreak management for influenza and COVID-19, enabling early isolation and treatment decisions where lab infrastructure is limited.
Key Findings
- Self-powered, pump-free microfluidic design using gravity and root-hair-like channels ensures equal distribution and fast transport.
- Cascaded RPA + lateral flow yields 40-min visual readouts for influenza A/B and SARS-CoV-2 with LoD ≈0.18 copies/µL.
- Retrospective clinical validation showed 93.2% sensitivity and 97.7% specificity; approximate per-test cost ≈$1.4.
Methodological Strengths
- Engineering innovation leveraging biomimicry with analytical validation (LoD, sensitivity/specificity) against clinical specimens.
- Clear cost and time-to-result characterization enabling translational assessment.
Limitations
- Clinical validation appears retrospective with unspecified sample size, requiring prospective multi-center studies.
- Performance assessed for three pathogens; broader respiratory panels need evaluation.
Future Directions: Prospective, multi-center validation including larger and diverse cohorts; expansion to additional respiratory targets; workflow integration in community and primary care settings.
In the postpandemic era, to tackle the engineering challenge from the concurrent outbreak of routine and emerging viral respiratory infections, microfluidic-chip-based point-of-care screening of multiple pathogens becomes essential for decentralized epidemic diagnosis and management. Toward real-world POCT, state-of-the-art microfluidic diagnostic devices are limited by the in-plane design of the fluidic circuit, which highly relies on external pumping apparatus for sample injection and distribution and thus greatly hampers their portability and accessibility. In this work, inspired by the pump-free water absorption mechanism of plant root hairs, we report a self-powered hand-held microfluidic sensing platform for simultaneous and rapid nucleic acid screening of viral respiratory pathogens, such as influenza A and B and SARS-CoV-2. This design lifts the liquid distribution port out of the principal plane of the microfluidic circuit to harness the power of gravity for sample injection and equal distribution. The root-hair-like liquid distribution channels enable fast and directional transport of limited biological specimen. Cascaded recombinase polymerase amplification and lateral flow assay yield rapid visual readout for the three pathogens in 40 min with a competitive detection sensitivity as low as 0.18 copies/μL, close to the detection limit of qPCR (gold standard). For real clinical specimens, retrospective research shows a sensitivity of 93.2% and a specificity of 97.7%. From an economic perspective, a unit cost down to 1.4 USD per test can generally be attained. This design leverages biomimetic structures to boost pump-free liquid transport for rapid and cost-efficient POCT for decentralized diagnostics, particularly in infrastructure-deficient areas.
3. Maternal Immunization With RSVpreF Vaccine: Effectiveness in Preventing Respiratory Syncytial Virus-associated Hospitalizations in Infants Under 6 Months in Argentina: Multicenter Case-control Study.
In a multicenter, prospective test-negative case-control study in Argentina (n=187 infants born after March 15, 2024), maternal RSVpreF vaccination reduced RSV-associated hospitalization in infants <6 months with adjusted effectiveness of 78.7% (95% CI 51.4–90.7) and shortened oxygen therapy (4 vs 7 days) and hospital stay (5 vs 8 days) among vaccinated cases.
Impact: Provides real-world effectiveness data supporting national maternal RSV vaccination programs and demonstrates reductions in both hospitalization risk and disease severity.
Clinical Implications: Supports maternal RSVpreF vaccination during late pregnancy to protect infants <6 months from RSV hospitalization and to attenuate disease severity (shorter oxygen therapy and stay).
Key Findings
- Adjusted vaccine effectiveness against RSV hospitalization in infants <6 months was 78.7% (95% CI 51.4–90.7).
- Maternal vaccination was less common among RSV-positive cases (17.6%) vs controls (44.8%).
- Among vaccinated RSV cases, oxygen therapy duration (4 vs 7 days) and length of stay (5 vs 8 days) were significantly reduced.
Methodological Strengths
- Prospective, multicenter design with active surveillance and test-negative case-control methodology.
- Adjustment for key confounders (age <3 months, prematurity, chronic respiratory disease).
Limitations
- Relatively small infant sample (n=187) in first season implementation; potential residual confounding.
- Limited to four pediatric referral hospitals; generalizability to broader settings requires confirmation.
Future Directions: Larger, multi-season evaluations to refine effectiveness estimates, assess duration of protection, and examine subgroups (e.g., preterm, comorbidities).
BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of morbidity and mortality in infants, particularly in those under 6 months. Starting March 2024, Argentina implemented the bivalent RSVpreF vaccine for pregnant women between 32.0 and 36.6 weeks of gestation during the RSV season. This report study aimed to assess the effectiveness of maternal immunization in preventing RSV-associated hospitalizations in infants under 6 months born to vaccinated and not vaccinated women, including their clinical and epidemiological characteristics. METHODS: A multicenter, prospective, observational, nested case-control study using a test-negative design was conducted. Data were collected through active epidemiological surveillance of respiratory infections in children under 18 years of age hospitalized at 4 pediatric referral hospitals in Argentina. RESULTS: Between January and October 2024, 1340 children were hospitalized for respiratory infections, including 187 infants born after March 15: 91 RSV-positive cases and 96 RSV-negative controls. RSV cases peaked in epidemiological week 26 (June). Compared to controls, RSV cases were younger ( P < 0.001) and had lower frequencies of comorbidities ( P < 0.001), prematurity ( P = 0.016) and chronic respiratory diseases ( P < 0.001). RSV maternal immunization was less frequent among RSV cases than controls (17.6% vs. 44.8%; P < 0.001). Vaccinated RSV cases had shorter duration of oxygen therapy (4 vs. 7 days; P < 0.001) and hospital stay (5 vs. 8 days; P < 0.001). The crude effectiveness of RSV immunization in infants under 6 months was 68.2% (95% confidence interval: 33.1%-84.9%) and 78.7% (95% confidence interval: 51.4%-90.7%) after adjustment for age under 3 months, prematurity and chronic respiratory disease. CONCLUSION: In its first season, Argentina's maternal RSVpreF immunization demonstrated substantial effectiveness in reducing RSV-associated hospitalizations in infants and decreasing RSV disease severity.